Altre lingue COMPASS Pathways plc

Azioni

CMPS

US20451W1018

Tempo reale stimato Cboe BZX Altri mercati azionari 18:19:45 09/07/2024			Variaz. 5gg	Var. 1 gen.
6,15 ^USD	-1,60%		+3,19%	-29,71%

26/06	Compass Pathways plc nomina Lori Englebert come Chief Commercial Officer, con effetto dall'8 luglio 2024	CI
05/06	COMPASS PATHWAYS PLC : Morgan Stanley ancora positivo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Compass Pathways appoints Lori Englebert as Chief Commercial Officer	26/06
Compass Pathways plc Appoints Lori Englebert as Chief Commercial Officer, Effective July 8, 2024	26/06
FDA panel to review psychedelic drug MDMA for first time	04/06
Clarify Pharma confirms name change to File Forge	22/05
COMPASS Pathways : 2024 AGM Voting Results	13/05
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights	08/05
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder	08/05
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder	08/05
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment	02/05
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression	29/04
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	29/04
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	18/04
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	18/04
Clarify Pharma to change name to File Forge Technology	17/04
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	02/04
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	02/04
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	01/04
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	01/04
ADRs End Lower; NuCana Slides 15%	28/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue COMPASS Pathways plc

Azioni

CMPS

US20451W1018

Altre lingue

Filtri